Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiodarone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.96 |
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 0.96 |
| ▸ | KDM5A | P29375 | 7/20 | 0.96 |
| ▸ | THRA | P10827 | 3/20 | 0.96 |
| ▸ | THRB | P10828 | 3/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | TP53 | P04637 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.96 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.96 |
| ▸ | KDM7A | Q6ZMT4 | 2/20 | 0.96 |
| ▸ | MLNR | O43193 | 1/20 | 0.96 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.96 |
| ▸ | PHF2 | O75151 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.96 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | FYN | P06241 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiodarone SCHEMBL12487240 | 0.98 | SIRT3 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL29361787 | 0.98 | SIRT3 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL5496372 | 0.98 | SIRT3 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL16284 | 0.98 | SIRT3 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL29362650 | 0.97 | ALDH1A1 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL29183902 | 0.97 | SIRT3 (0.98) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL41348 | 0.97 | ALDH1A1 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL29173757 | 0.97 | SIRT3 (0.98) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL28525007 | 0.97 | SIRT3 (0.98) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL19809514 | 0.96 | SIRT3 (0.96) | SIRT3KDM5ATHRATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-114671836-A | Synthesis method of amiodarone impurity C | 南京望知星医药科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-114441663-A | Method for screening protein positive compounds by using solid phase microextraction affinity selection mass spectrum | 中国科学院上海药物研究所 | 2022-05-06 | — | — | CN | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| CN-110672734-B | Analysis method of related substances in amiodarone hydrochloride injection | 合肥拓锐生物科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20200309767-A1 | HIGH-THROUGHPUT IMAGING-BASED METHODS FOR PREDICTING CELL-TYPE-SPECIFIC TOXICITY OF XENOBIOTICS WITH DIVERSE CHEMICAL STRUCTURES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-10-01 | — | — | US | disclosed |
| CN-110672734-A | Analysis method of related substances in amiodarone hydrochloride injection | 合肥拓锐生物科技有限公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-2796564-A1 | Method for determining hepatotoxicity of a compound. | Rijksinstituut Voor Volksgezondheid En Milieu (NL) | 2014-10-29 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | KCNH2 4822/4885SIRT3 507/4885KDM5A 2540/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | KCNH2 1639/4885SIRT3 848/4885KDM5A 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.